Format

Send to

Choose Destination
See comment in PubMed Commons below
Eur J Hum Genet. 2009 Aug;17(8):991-8. doi: 10.1038/ejhg.2009.10. Epub 2009 Feb 18.

Improving pharmacovigilance in Europe: TPMT genotyping and phenotyping in the UK and Spain.

Author information

1
Department of Human Molecular Genetics and Biochemistry, Tel-Aviv University, Israel.

Abstract

Thiopurine S-methyltransferase (TPMT) is the rate-limiting step in the conversion of thiopurine drugs including azathioprine (AZA) to inactive metabolites. Heritable deficiency of TPMT activity increases risk for adverse events, most notably, myelosuppression leading to leukopenia and neutropenic sepsis. The reported European Commission study was undertaken to identify current evidence for the clinical utility of testing for TPMT status and extent of uptake, by either genotyping or phenotyping, in the clinical setting. Data presented here for the UK and Spain indicate that there has been a considerable increase in the uptake of TPMT testing in recent years. There are some data that support routine TPMT testing before AZA prescribing for reducing AZA-related adverse events. Key data include evidence in favor of TPMT testing in addition to the current practice of routine monitoring for reducing the number of AZA-related episodes of myelosuppression, averting deaths from neutropenic sepsis and improving health-related quality of life. Further data are needed for determining the cost-effectiveness of routine TPMT testing.

PMID:
19223932
PMCID:
PMC2986553
DOI:
10.1038/ejhg.2009.10
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Nature Publishing Group Icon for PubMed Central
    Loading ...
    Support Center